10x Genomics preannounces Q2 rev ~$114.5M (-1% YoY), hires Jim Wilbur as CCO

10x Genomics, Inc.

2022-Q2 EPS reported -$0.94 revenue$229,105,000

Preliminary Q2 rev of ~$114.5M, down ~1% YoY from $115.8M and flat sequentially.
Americas rev grew 8% YoY to $70.9M; EMEA fell 11% to $25.6M; APAC fell 15% to $18.1M.
CEO says results 'fell short of our expectations'; full Q2 results and FY2022 guidance on Aug 8.
Appointed Jim Wilbur, Ph.D., as Chief Commercial Officer effective July 27; outgoing CCO Brad Crutchfield to transition through Dec 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.